Advertisement

Investigational New Drugs

, Volume 31, Issue 5, pp 1395–1396 | Cite as

Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer

  • Isamu OkamotoEmail author
  • Keisuke Aoe
  • Terufumi Kato
  • Yukio Hosomi
  • Akira Yokoyama
  • Fumio Imamura
  • Katsuyuki Kiura
  • Tomonori Hirashima
  • Makoto Nishio
  • Naoyuki Nogami
  • Hiroaki Okamoto
  • Hideo Saka
  • Nobuyuki Yamamoto
  • Naoto Yoshizuka
  • Risa Sekiguchi
  • Kazuhiro Kiyosawa
  • Kazuhiko Nakagawa
  • Tomohide Tamura
Erratum
  • 590 Downloads

Erratum to: Invest New Drugs

DOI 10.1007/s10637-013-9941-z

The original version of this article unfortunately contains some errors in the text describing the incidences of toxicities. The correct text is given below:

Safety

All 109 patients who received the initial combination therapy were assessable for safety analysis. The major adverse events for each treatment period (entire, initial combination, and maintenance periods) are shown in Table 3. Hematologic toxicities reaching ≥ grade 3 were neutropenia (56.9 %), thrombocytopenia (41.3 %), anemia (31.2 %), and leukopenia (22.0 %). Nonhematologic toxicities observed in more than half of patients included appetite loss (75.2 %), nausea (74.3 %), fatigue (67.9 %), and ALT increased (51.4 %), but the incidence of toxicities of grade 3 or higher was less than 10 %. The majority of adverse events were observed during the initial 4 cycles of pemetrexed and carboplatin combination therapy. Common toxicities ≥ grade 3 observed in the maintenance period were similar to those observed during the initial combination treatment period, including neutropenia (40.0 %), thrombocytopenia (16.7 %), leukopenia (11.7 %), and anemia (13.3 %). Newly emerged or deteriorated toxicities during maintenance periods were rarely observed. No treatment-related deaths were reported in this study.

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Isamu Okamoto
    • 1
    Email author
  • Keisuke Aoe
    • 2
  • Terufumi Kato
    • 3
  • Yukio Hosomi
    • 4
  • Akira Yokoyama
    • 5
  • Fumio Imamura
    • 6
  • Katsuyuki Kiura
    • 7
  • Tomonori Hirashima
    • 8
  • Makoto Nishio
    • 9
  • Naoyuki Nogami
    • 10
  • Hiroaki Okamoto
    • 11
  • Hideo Saka
    • 12
  • Nobuyuki Yamamoto
    • 13
  • Naoto Yoshizuka
    • 14
  • Risa Sekiguchi
    • 14
  • Kazuhiro Kiyosawa
    • 14
  • Kazuhiko Nakagawa
    • 1
  • Tomohide Tamura
    • 15
  1. 1.Department of Medical OncologyKinki University Faculty of MedicineOsaka-SayamaJapan
  2. 2.National Hospital Organization Yamaguchi-Ube Medical CenterYamaguchiJapan
  3. 3.Kanagawa Cardiovascular and Respiratory CenterKanagawaJapan
  4. 4.Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyoJapan
  5. 5.Niigata Cancer Center HospitalNiigataJapan
  6. 6.Osaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  7. 7.Okayama University HospitalOkayamaJapan
  8. 8.Osaka Prefectural Medical Center for Respiratory and Allergic DiseasesOsakaJapan
  9. 9.Cancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan
  10. 10.National Hospital Organization Shikoku Cancer CenterEhimeJapan
  11. 11.Yokohama Municipal Citizen’s HospitalKanagawaJapan
  12. 12.National Hospital Organization Nagoya Medical CenterAichiJapan
  13. 13.Shizuoka Cancer CenterShizuokaJapan
  14. 14.Eli Lilly Japan K.K.HyogoJapan
  15. 15.National Cancer Center HospitalTokyoJapan

Personalised recommendations